Company Valuation: Aprogen Medicines Inc.

Data adjusted to current consolidation scope
Fiscal Period: December 2020 2021 2022 2023 2024 2025
Market Cap 1 374,121 335,573 399,707 234,315 219,892 215,057
Change - -10.3% 19.11% -41.38% -6.16% -2.2%
Enterprise Value (EV) 1 222,313 254,743 442,443 318,048 289,933 352,159
Change - 14.59% 73.68% -28.12% -8.84% 21.46%
P/E -7.46x -18.1x -3.45x -4.07x -3.44x -2.95x
PBR 1.17x 1x 1.86x 1.59x 1.39x 1.36x
PEG - 0.3x -0x 0.1x 0.76x -0.62x
Capitalization / Revenue 2.94x 2.38x 5.1x 1.56x 1.46x 1.82x
EV / Revenue 1.75x 1.8x 5.65x 2.11x 1.93x 2.99x
EV / EBITDA 31.1x -395x -5x -4.83x -4.39x -4.89x
EV / EBIT 78.2x -52x -3.78x -3.35x -3.21x -3.68x
EV / FCF -4.57x -1.98x -3.05x -14.7x -6.61x -3.85x
FCF Yield -21.9% -50.6% -32.8% -6.81% -15.1% -26%
Dividend per Share 2 - - - - - -
Rate of return - - - - - -
EPS 2 -12,334 -4,193 -7,461 -3,540 -3,379 -3,540
Distribution rate - - - - - -
Net sales 1 127,143 141,247 78,349 150,578 150,114 117,974
EBITDA 1 7,152 -644.7 -88,552 -65,899 -66,017 -71,974
EBIT 1 2,844 -4,902 -116,944 -94,970 -90,322 -95,571
Net income 1 -46,490 -18,002 -98,657 -55,619 -58,079 -70,202
Net Debt 1 -151,809 -80,830 42,736 83,732 70,041 137,102
Reference price 2 92,025.00 75,825.00 25,740.00 14,400.00 11,640.00 10,455.00
Nbr of stocks (in thousands) 4,065 4,426 15,529 16,272 18,891 20,570
Announcement Date 3/19/21 3/23/22 3/27/23 3/19/24 3/13/25 3/23/26
1KRW in Million2KRW
Estimates


P/E (Y) EV / Sales (Y) EV / EBITDA (Y) Dividend Yield (Y) Capi.($)
- - - - 31.86M
28.44x5.1x18.59x0.92% 111B
29.39x4.61x17.46x1.83% 83.61B
29.04x3.32x19.16x0.72% 63.58B
40.86x6.38x28.14x1.87% 59.56B
36.88x7.46x21.85x-.--% 53.59B
24x4.53x15.6x2.64% 33.25B
20.68x1.77x12.74x2.27% 30.08B
29.33x3.89x14.65x0.12% 28.51B
21.88x3.18x13.69x1.07% 26.5B
Average 28.94x 4.47x 17.99x 1.27% 48.98B
Weighted average by Cap. 30.03x 4.78x 18.93x 1.23%

Y-o-Y evolution of P/E

Valuation ratios - P/E - Aprogen Medicines Inc.

Historical PBR trend

Valuation ratios - PBR - Aprogen Medicines Inc.

Evolution Enterprise Value / Sales

Valuation ratios - VE_REV - Aprogen Medicines Inc.

Change in Enterprise Value/EBITDA

Valuation ratios - VE_EBITDA - Aprogen Medicines Inc.

  1. Stock Market
  2. Stocks
  3. A007460 Stock
  4. Valuation Aprogen Medicines Inc.